gs-5829
Showing 1 - 1 of 1
Advanced Estrogen Receptor Positive HER2- Breast Cancer Trial in United States (GS-5829, Exemestane, Fulvestrant)
Terminated
- Advanced Estrogen Receptor Positive HER2- Breast Cancer
- GS-5829
- +2 more
-
Stanford, California
- +5 more
Jul 15, 2019